Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pancreatic Clamp Study Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT07560150
View directory record Official record
Conditions
Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions
I004, NovoLog
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 6:39 AM EDT
Completed No phase listed Observational

Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

NCT03195400
View directory record Official record
Conditions
IGT - Impaired Glucose Tolerance, T2D
Interventions
Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test, Hyperinsulinemic Euglycemic Clamp and 2H20
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 23, 2026, 6:39 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

NCT07494084
View directory record Official record
Conditions
Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment
Interventions
Metyrapone And Hydrocortisone, Dextrose, insulin
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

Experimental Study to Validate the Modified Glucose Disposal Test

NCT01152372
View directory record Official record
Conditions
Diabetes
Interventions
Insulin, glucose and staple isotopes
Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 23, 2026, 6:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

NCT07212868
View directory record Official record
Conditions
Non-Diabetic
Interventions
REMD-477 versus Placebo, Exogenous glucagon versus saline infusion
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 4 Interventional Results available

The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans

NCT00179400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone, Placebo, Pancreatic Clamp Study
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 23, 2026, 6:39 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

NCT03685773
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders
Interventions
Diazoxide, Placebo (for diazoxide), Nicotinic acid
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 23, 2026, 6:39 AM EDT
Not yet recruiting Phase 1 Interventional

Human Models of Selective Insulin Resistance: Pancreatic Clamp

NCT06558422
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

NCT00752180
View directory record Official record
Conditions
Diabetes
Interventions
Wosulin R, Actrapid
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Glucagon on Hepatic Metabolism

NCT05500586
View directory record Official record
Conditions
Obesity, Type2diabetes, NAFLD
Interventions
Glucagon response study
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

NCT03170544
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Not applicable Interventional

Exercise Physiology Study

NCT03090451
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Aerobic Exercise
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 6:39 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Central Mechanisms That Regulate Glucose Metabolism in Humans

NCT01028846
View directory record Official record
Conditions
Type 2 Diabetes, Glucose Metabolism Disorders, Glucose, High Blood
Interventions
Diazoxide, Placebo
Drug
Lead sponsor
Meredith Hawkins
Other
Eligibility
21 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

Pancreatic Clamp in NAFLD

NCT05724134
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 6:39 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion

NCT03998709
View directory record Official record
Conditions
Healthy
Interventions
Somatostatin, Dextrose, Insulin, Intralipid
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Insulin Secretion in Diabetes Before and After Glycemic Control

NCT00469833
View directory record Official record
Conditions
Diabetes, Hyperglycemia
Interventions
insulin glargine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
30 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 23, 2026, 6:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Alpelisib Challenge Test (ACT)

NCT07778524
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions
Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 2 Interventional Results available

A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

NCT02535715
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ORMD-0801 capsules- 2x8mg, ORMD-0801 capsules- 3x8mg, ORMD-0801 capsules- 1x16mg
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.

NCT00596063
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Wosulin R, Novolin R
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects

NCT00772265
View directory record Official record
Conditions
Diabetes
Interventions
Wosulin N, Novolin N
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

TAK-329 Glucose Clamp Study

NCT01311076
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
TAK-329, Insulin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 23, 2026, 6:39 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Insulin Modulation of fMRI Connectivity in Healthy Adults

NCT02982551
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Insulin, Taste Task, Magnetic Resonance Imaging, Dextrose
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 23, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

NCT01357603
View directory record Official record
Conditions
Type1 Diabetes
Interventions
Glargine
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 23, 2026, 6:39 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Regulation of Endogenous Glucose Production by Central KATP Channels

NCT03540758
View directory record Official record
Conditions
Diabetes Mellitus, Glucose Metabolism Disorders
Interventions
Diazoxide, Nicotinic acid, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 23, 2026, 6:39 AM EDT